Trial Profile

A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Apr 2025 Results presented in a Verge Genomics media release.
07 Apr 2025 According to a Verge Genomics media release, study is on track to deliver efficacy and safety results in the second half of this year.
07 Apr 2025 According to a Verge Genomics media release, the company will present digital clinical biomarker endpoints data in a platform session at the 77th Annual Meeting of the American Academy of Neurology in San Diego on Tuesday, April 8, 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com